Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P15509
UPID:
CSF2R_HUMAN
Alternative names:
CDw116
Alternative UPACC:
P15509; A7J003; A8KAM1; B4DW68; J3JS76; J3JS77; O00207; Q14429; Q14430; Q14431; Q16564
Background:
Granulocyte-macrophage colony-stimulating factor receptor subunit alpha, also known as CDw116, plays a pivotal role in the immune system. It acts as a low affinity receptor for granulocyte-macrophage colony-stimulating factor, transducing signals that lead to the proliferation, differentiation, and functional activation of hematopoietic cells.
Therapeutic significance:
The protein's malfunction is linked to Pulmonary surfactant metabolism dysfunction 4, a rare lung disorder characterized by impaired surfactant homeostasis. Understanding the role of Granulocyte-macrophage colony-stimulating factor receptor subunit alpha could open doors to potential therapeutic strategies for this severe respiratory distress.